Apollomics Inc. (APLM)

Pharmaceutical Preparations · market cap $50M · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-01-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Apollomics Inc. (APLM) is a micro-cap pharmaceutical company with 13 employees and a market cap of approximately $50M at a share price near $15.70. Its sole disclosed pipeline asset is APL-101 Oral Capsules, currently in Phase 2 development for solid tumors. The nearest near-term event is a July 24, 2026 earnings release rated 5/10 on impact.

The catalyst path

2027-01-31 (est.)Phase 2 · APL-101imp 7/10

Pipeline

Asset	Phase	Indication
APL-101 Oral Capsules	Phase 2	Solid Tumors
APL-101	Phase 2	Metastatic Non Small Cell Lung Cancer

Price & technical context

3-month

+23.8%

6-month

+57.4%

12-month

+35.4%

52-wk range

$11.61–$36.65

vs 50-day MA

+12.4%

vs 200-day MA

+33.7%

Realized vol

131.1%

Max drawdown

-79.7%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for APLM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.